GlassScriptPhysician profile
Jennifer Ling
NPI 1366860025
$8,594.39
in general payments reported to CMS, 2019-2025
13 companies · $2,915 in 2025
The $2,915 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.70 · 2023: $323 · 2024: $5,288 · 2025: $2,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,589 · Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,589.00 |
| Food and Beverage | $1,936.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $6,854.96 | 2023-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Istent Trabecular Micro-Bypass System Model Is3 |
| Harrow Eye, LLC | $542.93 | 2023-2025 | Iheezo |
| Rxsight INC | $312.94 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Abbvie INC. | $238.02 | 2023-2025 | |
| Ocular Therapeutix, INC. | $170.04 | 2023-2025 | Dextenza |
| Dompe US, INC. | $119.86 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $94.83 | 2023-2025 | Envista Mx60 Iol, Vyzulta, Miebo |
| Alcon Vision LLC | $94.71 | 2019-2025 | Clareon Panoptix Pro |
| Sun Pharmaceutical Industries INC. | $57.91 | 2025 | |
| Rayner Intraocular Lenses Limited | $45.79 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Tarsus Pharmaceuticals, INC. | $29.02 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $18.11 | 2024 | |
| Amgen INC. | $15.27 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.